scholarly article | Q13442814 |
review article | Q7318358 |
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1444-1450 | |
P577 | publication date | 1990-09-01 | |
P1433 | published in | The Journal of the American Medical Association | Q1470970 |
P1476 | title | NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer | |
P478 | volume | 264 |
Q83172673 | 3-T MRI with phased-array surface coil in the local staging of rectal cancer |
Q35993810 | A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas |
Q36125075 | A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer. |
Q37355442 | A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer |
Q36667516 | A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer |
Q36616783 | A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. |
Q34147006 | A team approach to improving colorectal cancer services using administrative health data |
Q81381752 | Access to care and satisfaction in colorectal cancer patients |
Q35133471 | Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough? |
Q34488296 | Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis |
Q33860245 | Adjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR patterns of care study |
Q37076532 | Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. |
Q37026757 | Adjuvant and neoadjuvant chemoradiation or radiotherapy in rectal cancer--a review focusing on open questions |
Q34627277 | Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer |
Q36101826 | Adjuvant and neoadjuvant treatment of resectable, locally advanced, rectal carcinoma with radiation therapy and chemotherapy |
Q34255956 | Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α |
Q26775099 | Adjuvant chemotherapy for rectal cancer: Is it needed? |
Q34631210 | Adjuvant chemotherapy for stage II colon cancer with poor prognostic features |
Q30780611 | Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data |
Q33374271 | Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis |
Q39601118 | Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer |
Q46896343 | Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection |
Q84396469 | Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial? |
Q36239072 | Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline |
Q36130803 | Adjuvant therapy for adenocarcinoma of the rectum |
Q81679190 | Adjuvant therapy for colon cancer |
Q83161252 | Adjuvant therapy for colon cancer |
Q42868640 | Adjuvant therapy for colon cancer: learning from the past to inform the future |
Q37462241 | Adjuvant therapy for rectal cancer |
Q35767246 | Adjuvant therapy for rectal cancer in the elderly |
Q91831015 | Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions |
Q37072502 | Adjuvant treatment of rectal cancer: improving patient selection |
Q36025983 | Advances and challenges in treatment of locally advanced rectal cancer |
Q55427621 | Advances in the management of rectal cancer. |
Q45386283 | Age and factors associated with access and time to post-operative adjuvant chemotherapy in colon cancer: a French epidemiological study |
Q47851170 | Ageism in rectal carcinoma? Treatment and outcome variations |
Q71626706 | Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil |
Q31106341 | An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. |
Q27024427 | An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? |
Q33607161 | Anatomic basis of sharp pelvic dissection for curative resection of rectal cancer |
Q33866565 | Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002) |
Q73451649 | Angiogenesis and dendritic cell density are not correlated with metachronous distant metastasis in curatively operated rectal cancer |
Q80713667 | Are we undertreating rectal cancer in the elderly? An epidemiologic study |
Q45256282 | Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer |
Q36534769 | Association between the availability of medical oncologists and initiation of chemotherapy for patients with stage III colon cancer |
Q47627901 | Better Late than Never? Adherence to Adjuvant Therapy Guidelines for Stage III Colon Cancer in an Underserved Region |
Q55353989 | CDX2 expression is concordant between primary colorectal cancer lesions and corresponding liver metastases independent of chemotherapy: a single-center retrospective study in Japan. |
Q36611654 | CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II. |
Q31138958 | Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base |
Q30822062 | Cancer registries can provide evidence-based data to improve quality of care and prevent cancer deaths. |
Q58914739 | Cancer surgery in the elderly |
Q64117622 | Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance) |
Q36394634 | Characteristics affecting survival after locally advanced colorectal cancer in Quebec |
Q73236924 | Chemotherapy of Colorectal Cancer |
Q35978879 | Chemotherapy use in stage III colon cancer: a National Cancer Database analysis |
Q42027206 | Chronic myelogenous leukemia after postoperative adjuvant S-1 therapy for rectal cancer: a case report |
Q33794082 | Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study |
Q47121565 | Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma |
Q36871965 | Colon cancer stem cells: controversies and perspectives |
Q37172593 | Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study |
Q33947455 | Colorectal cancer treatment |
Q34844579 | Colorectal cancer: from epidemiology to current treatment |
Q33408350 | Combining information from cancer registry and medical records data to improve analyses of adjuvant cancer therapies |
Q30422446 | Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer |
Q45716452 | Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection |
Q30422095 | Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. |
Q35071455 | Completion of therapy by Medicare patients with stage III colon cancer |
Q35585939 | Conclusions from a study of venous invasion in stage IV colorectal adenocarcinoma |
Q37145772 | Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces |
Q35445092 | Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014 |
Q47737573 | Controversial issues in radiotherapy for rectal cancer: a systematic review |
Q47235105 | Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study |
Q44492666 | Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany |
Q26824553 | Current treatment of rectal cancer adapted to the individual patient |
Q50422213 | Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer. |
Q70504417 | DNA aneuploidy is an independent factor of poor prognosis in pancreatic and peripancreatic cancer |
Q41823848 | Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer |
Q35769649 | Detection of venous invasion in surgical specimens of colorectal carcinoma: the efficacy of various types of tissue blocks |
Q84049962 | Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease |
Q91691310 | Diabetic ketoacidosis caused by fulminant type 1 diabetes during adjuvant chemotherapy for colon cancer: A case report |
Q53584611 | Diagnostic value of measuring liver volume for detecting occult hepatic metastases from colorectal or gastric cancer. |
Q35071410 | Differences among the elderly in the treatment costs of colorectal cancer: how important is race? |
Q80562303 | Do young colon cancer patients have worse outcomes? |
Q73050010 | Does anastomotic leakage affect functional outcome after rectal resection for cancer? |
Q43923184 | Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer |
Q36711475 | Drug treatment of colorectal cancer. Current status |
Q53137607 | Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. |
Q37133361 | Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer. |
Q38298226 | Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy |
Q83821349 | Effects of postoperative adjuvant radiotherapy on recurrence and survival in stage III rectal cancer |
Q33746878 | Efficacy of postoperative concurrent chemoradiation for resectable rectal cancer: a single institute experience |
Q34282863 | Emergency surgery for colorectal cancer does not result in nodal understaging compared with elective surgery |
Q30484649 | Endorectal ultrasound: its role in the diagnosis and treatment of rectal cancer |
Q27014984 | Epigenetics meets radiation biology as a new approach in cancer treatment |
Q47950050 | ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. |
Q52949271 | Evaluating toxicity in neoadjuvant radio-chemotherapy of rectal cancer |
Q35067307 | Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis |
Q39390635 | Evolving role of neoadjuvant therapy in rectal cancer |
Q30502576 | Explaining black-white differences in receipt of recommended colon cancer treatment |
Q53061569 | Extended lymph node dissection in colorectal cancer surgery. Reliability and reproducibility in assessments of operative reports. |
Q82904914 | Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients |
Q34778099 | FOLFIRI Is Tolerable after Subtotal Colectomy - A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer |
Q36609950 | Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. |
Q37416816 | Feasibility of adequate resectable rectal cancer treatment in a third-level hospital |
Q37508622 | Follow-up plans after treatment of primary colon and rectum cancer |
Q36104000 | Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy? |
Q38651907 | Health care disparities among octogenarians and nonagenarians with stage II and III rectal cancer. |
Q37701707 | High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. |
Q47128241 | Hospital academic status and value of care for nonmetastatic colon cancer |
Q36416460 | How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study |
Q34465977 | Hypomethylation-associated up-regulation of TCF3 expression and recurrence in stage II and III colorectal cancer |
Q80955233 | Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer |
Q35693475 | Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival |
Q89502186 | Impact of Adjuvant Therapy Type on Survival in Stage II/III Rectal Cancer Without Preoperative Chemoradiation: A Korean Multicenter Retrospective Study |
Q47140514 | Impact of neoadjuvant and adjuvant radiotherapy on disease-specific survival in patients with stages II-IV rectal cancer |
Q42794535 | Impact of neoadjuvant chemoradiation on pathologic response and survival of patients with locally advanced rectal cancer |
Q33791360 | Impact of the new AJCC staging system and adjuvant treatment in rectal cancer |
Q38474003 | Impact on Prognosis of Lymph Node Micrometastasis and Isolated Tumor Cells in Stage II Colorectal Cancer |
Q34932625 | Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer |
Q47959037 | Improved survival in an Asian cohort of young colorectal cancer patients: an analysis of 523 patients from a single institution |
Q36352848 | In search of synergy: strategies for combining interventions at multiple levels |
Q34469631 | In the era of total mesorectal excision: adjuvant radiotherapy may be unnecessary for pT3N0 rectal cancer |
Q46616424 | Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha |
Q41735144 | Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009. |
Q33646009 | Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings |
Q37463523 | Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States. |
Q36306673 | Interval between Surgery and Radiation Therapy Is an Important Prognostic Factor in Treatment of Rectal Cancer. |
Q33909869 | Is acute dyspnea related to oxaliplatin administration? |
Q51803069 | Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute. |
Q37533235 | Is adjuvant radiotherapy warranted in resected pT1-2 node-positive rectal cancer? |
Q36300533 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer |
Q37946252 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. |
Q36324953 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. |
Q47712300 | Karyopherin α-2 is a reliable marker for identification of patients with high-risk stage II colorectal cancer |
Q38453832 | LEMMA: a language for easy medical models analysis |
Q42601143 | Laparoscopic surgery for the curative treatment of rectal cancer: results of a Chinese three-center case-control study |
Q81688022 | Late outcomes of colorectal cancer treatment: a FECS-EUROCARE study |
Q36972881 | Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer |
Q37088033 | Local recurrence after rectal cancer treatment in Manitoba |
Q34571377 | Local staging of rectal cancer: the current role of MRI. |
Q43436444 | Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer |
Q45017990 | Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer |
Q74492663 | Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy |
Q34766318 | Long-term survival and recurrence outcomes following surgery for distal rectal cancer. |
Q85084914 | Long-term survival results of surgery alone versus surgery plus UFT (Uracil and Tegafur)-based adjuvant therapy in patients with stage II colon cancer |
Q33302869 | Longitudinal, population-based study of racial/ethnic differences in colorectal cancer survival: impact of neighborhood socioeconomic status, treatment and comorbidity |
Q35666090 | Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy |
Q35703248 | Management of rectal cancer |
Q36097091 | Management of stage II/III rectal cancer |
Q34751755 | Mature Results of a Prospective Randomized Trial Comparing 5-Flourouracil with Leucovorin to 5-Flourouracil with Levamisole as Adjuvant Therapy of Stage II and III Colorectal Cancer- The Israel Cooperative Oncology Group (ICOG) Study |
Q36500021 | Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. |
Q90429127 | MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside |
Q33868392 | Modern management of rectal cancer: a 2006 update |
Q36615471 | Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study |
Q90415336 | Molecular Imaging of Cancer Stem Cells for Assessment of Rectal Cancer |
Q36551503 | Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer |
Q55013743 | Multicenter, phase II clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage III colorectal cancer. |
Q35920508 | Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future |
Q37408813 | Neo-adjuvant radiotherapy in rectal cancer |
Q39172475 | Neoadjuvant Treatment for Locally Advanced Rectal Cancer: New Concepts in Clinical Trial Design |
Q37292444 | Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens |
Q28365788 | Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience |
Q26796352 | Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer |
Q41692918 | Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. |
Q50000489 | Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial |
Q42121875 | Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors |
Q37158143 | Neoadjuvant treatment of rectal cancer: where are we now? |
Q33849039 | Neoadjuvant vs adjuvant pelvic radiotherapy for locally advanced rectal cancer: Which is superior? |
Q35095353 | New developments in therapy for colorectal cancer |
Q43138615 | New perspectives in treatment decision for integrated management of rectal cancer: multimodal research for multimodal treatments |
Q48571098 | Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2-T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME). |
Q35951764 | Oncologic Outcomes and Risk Factors for Recurrence after Tumor-specific Mesorectal Excision of Rectal Cancer: 782 Cases |
Q36403043 | Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens |
Q79378349 | Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival |
Q34247372 | Optimising treatment for resectable rectal cancer: is preoperative therapy beneficial? |
Q35779359 | Overall Survival of Stage III Colon Cancer with Only One Lymph Node Metastasis Is Independently Predicted by Preoperative Carcinoembryonic Antigen Level and Lymph Node Sampling Status. |
Q36511751 | Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma |
Q38403572 | Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. |
Q36365456 | Pathological correlation with diffusion restriction on diffusion-weighted imaging in patients with pathological complete response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results |
Q41068800 | Pattern of recurrence in rectal carcinoma: implications for the design of (future) studies on adjuvant therapy |
Q36824126 | Patterns of Colorectal Cancer Care in the United States: 1990-2010. |
Q37256284 | Patterns of Pelvic Radiotherapy in Patients with Stage II/III Rectal Cancer |
Q34771979 | Patterns of local recurrence in rectal cancer after a multidisciplinary approach |
Q36370711 | Patterns of recurrence following liver resection for colorectal metastases: effect of primary rectal tumor site |
Q47580575 | Pelvic sidewall involvement in recurrent rectal cancer |
Q55455144 | Perioperative Serum Carcinoembryonic Antigen Ratio Is a Prognostic Indicator in Patients With Stage II Colorectal Cancer. |
Q53179192 | Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. |
Q34344547 | Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. |
Q33799243 | Population-based study of effectiveness of neoadjuvant radiotherapy on survival in US rectal cancer patients according to age. |
Q44841956 | Positive peritoneal washing cytology is a potential risk factor for the recurrence of curatively resected colorectal cancer |
Q37564794 | Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model. |
Q24201072 | Postoperative adjuvant chemotherapy in rectal cancer operated for cure |
Q80111840 | Postoperative irradiation for rectal cancer increases the risk of small bowel obstruction after surgery |
Q35588277 | Pre-operative and post-operative radiotherapy and rectal cancer |
Q39823759 | Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy |
Q43969739 | Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy |
Q35866157 | Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium |
Q35537282 | Predictors of referral for adjuvant therapy for colorectal cancer. |
Q86823678 | Preoperative chemoradiotherapy for clinically diagnosed T3N0 rectal cancer |
Q53528706 | Preoperative evaluation of pelvic lateral lymph node of patients with lower rectal cancer: comparison study of MR imaging and CT in 53 patients. |
Q57035666 | Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma |
Q37158196 | Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. |
Q33406632 | Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society |
Q36616636 | Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II). |
Q43406325 | Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer |
Q45288286 | Present treatment strategies for rectal carcinoma |
Q37656817 | Primary colonic signet ring cell carcinoma in a young patient. |
Q34928303 | Profiling hospitals by survival of patients with colorectal cancer |
Q37600725 | Prognostic Value of E-cadherin-, CD44-, and MSH2-associated Nomograms in Patients With Stage II and III Colorectal Cancer |
Q37730438 | Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review |
Q34202487 | Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy |
Q35596125 | Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer |
Q77620951 | Prognostic significance of tumor markers in colorectal cancer patients: DNA index, S-phase fraction, p53 expression, and Ki-67 index |
Q50079903 | Prognostic value of the detection of lymph node micrometastases in colon cancer |
Q33589855 | Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy--long-term results |
Q34734413 | Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community |
Q34026017 | Quality-of-life and surgical treatments for rectal cancer--a longitudinal analysis using the California Cancer Registry |
Q34360966 | Quantifying limitations in chemotherapy data in administrative health databases: implications for measuring the quality of colorectal cancer care. |
Q37536719 | Quantitative proteomics reveals that distant recurrence-associated protein R-Ras and Transgelin predict post-surgical survival in patients with Stage III colorectal cancer |
Q35916635 | Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer |
Q43636065 | Racial and ethnic disparities in outcomes with radiation therapy for rectal adenocarcinoma |
Q36503071 | Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? |
Q30418988 | Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults |
Q57272317 | Racial disparities in stage-specific colorectal cancer mortality: 1960-2005 |
Q92716703 | Radiation therapy for rectal cancer |
Q83419632 | Radiotherapy in rectal cancer: development, adequacy and radiotherapy utilisation rate. A comparative analysis with the most frequent tumour sites |
Q83071483 | Radiotherapy: Preoperative chemoradiotherapy for rectal cancer |
Q34296147 | Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review |
Q30484651 | Rectal cancer staging |
Q47110810 | Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer |
Q58913807 | Reduced Lymph Node Yield in Rectal Carcinoma Specimen After Neoadjuvant Radiochemotherapy Has No Prognostic Relevance |
Q35878821 | Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer |
Q36572508 | Relationship between diversion colitis and quality of life in rectal cancer |
Q44755635 | Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology |
Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
Q33627785 | Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes |
Q28384895 | Secular trends in mortality from common cancers in the United States by educational attainment, 1993-2001 |
Q89502167 | Selection of Adjuvant Treatment Without Neoadjuvant Chemoradiotherapy for Patients With Rectal Cancer: Room for Further Investigation |
Q44226585 | Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified: analysis of local recurrence |
Q88881301 | Selective use of radiation for locally advanced rectal cancer: one size does not fit all |
Q31140547 | Sentinel lymph node mapping in colon cancer |
Q33745103 | Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer |
Q35103614 | Stage III colon cancer at Baylor University Medical Center at Dallas and the Baylor Sammons Cancer Center: experience from 2000 to 2004 |
Q26823217 | Stem cells, colorectal cancer and cancer stem cell markers correlations |
Q37072492 | Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. |
Q37310011 | Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence |
Q33897653 | Surgery and adjuvant chemotherapy use among veterans with colon cancer: insights from a California study. |
Q45038133 | Surgical therapy of liver metastases. Therapeutic procedures, results and prognostic factors |
Q55082844 | Survival Contradiction Between Stage IIA and Stage IIIA Rectal Cancer: A Retrospective Study. |
Q35011194 | Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population |
Q51770013 | Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. |
Q44447446 | Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum. |
Q28084403 | Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease |
Q73164021 | T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy |
Q36216141 | The C-Reactive Protein to Albumin Ratio as a Predictor of Severe Side Effects of Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients |
Q37011670 | The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group |
Q49531454 | The Impact of Novel Radiation Treatment Techniques on Toxicity and Clinical Outcomes In Rectal Cancer |
Q30452275 | The accuracy of multi-detector row computerized tomography in staging rectal cancer compared to endoscopic ultrasound |
Q37913985 | The current landscape of locally advanced rectal cancer |
Q33432354 | The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study |
Q36895084 | The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients |
Q36101379 | The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer |
Q35306161 | The extramural metastasis might be categorized in lymph node staging for colorectal cancer. |
Q34216044 | The impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients. |
Q44985394 | The modern abdominoperineal excision: the next challenge after total mesorectal excision |
Q38359377 | The neoadjuvant treatment of rectal cancer: a review |
Q50494337 | The pathological assessment of mesorectal excision: implications for further treatment and quality management. |
Q37462225 | The pathologist's role in rectal cancer patient assessments |
Q38965328 | The positive impact of surgical quality control on adequate lymph node harvest by standardized laparoscopic surgery and national quality assessment program in colorectal cancer |
Q37670882 | The role of 3-D endorectal ultrasound in rectal cancer: our experience |
Q48254485 | The role of adjuvant chemotherapy in stage II colorectal cancer patients |
Q37694845 | The survival and clinicopathological differences between patients with stage IIIA and stage II rectal cancer: An analysis of 12,036 patients in the SEER database |
Q34234928 | Therapeutic approaches in the management of locally advanced rectal cancer |
Q92189101 | Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy |
Q87884153 | Total number of lymph node metastases is a more significant risk factor for poor prognosis than positive lateral lymph node metastasis |
Q43648443 | Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1. |
Q30417975 | Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation |
Q36351882 | Treatment of locally advanced rectal cancer: controversies and questions |
Q38170032 | Treatment of stage II-III rectal cancer patients |
Q33552813 | Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients |
Q37699262 | Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients |
Q37340518 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer |
Q47141257 | Use of Adjuvant Chemotherapy among Stage II Colon Cancer Patients in 10 Population-Based National Program of Cancer Registries |
Q46884830 | Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study |
Q58130112 | Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States |
Q36343876 | Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging |
Q37524471 | Wound dehiscence after abdominoperineal resection for low rectal cancer is associated with decreased survival |
Q77537083 | [Adjuvant and neoadjuvant therapy of rectal carcinoma. The current status] |
Q77335763 | [An addendum to the article by C. Rödel, W. Hohenberger, R. Sauer. Adjuvant and neoadjuvant radiochemotherapy of rectal carcinoma. Strahlenther Onkol 1998; 174: 497-504 (Nr. 10)] |
Q72519240 | [Developments up to now and current status of adjuvant chemo- and radiotherapy in colonic and rectal carcinoma] |
Q80700849 | [Problems in the treatment of upper rectal carcinoma] |
Q50936160 | [The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma]. |
Search more.